Australia's largest stock trading and investment forum Australia's #1 stock forum

AT1

0.00%

2.7¢ atomo diagnostics limited

Definitely a good question to proffer the company. I agree it...

First 329 Last

Share
Profile

Follow
Tamaruler

247 Posts.

80

17/11/20

19:42

Post #: 48941036
Share

Originally posted by FinFree101: ↑

Note: This information is un-verified by AT1 company directly(I don't plan to ask them until next Q&A opp but of course any SH can do so).

13 Nov'20: AccBio partner Q1'FY21 report (KRX) (in Korean)
http://dart.fss.or.kr/dsaf001/main.do?rcpNo=20201113000683

I won't go through the whole report here as it is all AccBio biz (however it is an interesting read to see how AT1's 2nd largest diagnostics partner is continue to benefit + gear up in the ongoing Covid19 surges, future test strategy areas, tests in dev + several pages on malaria market status, how its positioning itself etc...never know which direction AT1's partnership will head towards next, so handy to file away)

No mention of specific Covid19 Ab tests (which has AT1 device OEM supply).

......I did find a bread crumb (or a whole slice?) though concerning AT1 company.......

Page 25

+
Page 28

Sooo, in my view, this AccBio-AT1 HIV test topic has not been announced formally, because:

- falls under existing AccBio-AT1 licence manufacturing deal announced in 2017 (for Pascal devices) + there are no commercialised tests (yet) that would trigger a market sensitive ann. We don't have any details for this agreement, since pre-IPO, nor which tests it was targeted for (though HCV, Covid19 Ab tests were my thoughts)

- seems like the AccBio-AT1 manufacturing licence is supposed to give % of rev for any commercialised tests? HIV market being one of the first tests presumably?

What's not 100% clear from above info, is whether AccBio has developed their own HIV test strip (+ AT1 device); it does read like they have done this though as its noted under 'R&D' section & expenses?
OR
AccBio is using AT1's complete HIV test, which it plans to licence manufacture (option doesn't make sense to me since AT1's test is already developed + EU CE approved, so AccBio would have no need to re-do testing or R&D)?

If AccBio has developed its own HIV test (+ AT1 device manufacture) for EU market...this doesn't make sense to me biz wise. Why would AT1 allow its own (much larger partner) to become a competitor for one of it core test lines + possibly impact existing Owen Mumford/Viatris partnership rev, by enabling AccBio?

I would think what AT1 gains from wholesaling its own complete tests via partners would be greater return than AccBio % rev share per device? Any thoughts on this? Maybe I am missing something obvious here...

In any case, until something gets announced, this is un-verified info for me...though I will add a TBA line in my pipeline sheet

Expand

Definitely a good question to proffer the company. I agree it doesn't make sense for AB to spend money creating their own test strip when they can get the whole completed device from us. Not sure why they'd want to compete against us or why we'd let them?

Still waiting to hear about who these new OEM's are that John referenced in the NWR presentation and the FDA approval for the Ab devices!

AT1 Price at posting: 33.0¢ Sentiment: Buy Disclosure: Held
4 Upvote

0 Great analysis

Reply

Top Stories

SBW

Shekel Brainweigh CEO Nir Leshem weighs in on AI adoption ahead of FY25

RDN

If you thought lithium was dead, think again. The Pilbara will be central to the next upswing

With financials holding the fort, materials must step up with some heavy lifting to stimulate stocks

AML

Cultural heritage agreement puts Walford Creek exploration back on the map

STX

Strike Energy secures $153 million for Perth Basin gas projects

There are more pages in this discussion • 2,105 more messages in this thread...

First 329 Last

Add AT1 (ASX) to my watchlist

(20min delay)
Last 2.7¢		Change 0.000(0.00%)		Mkt cap ! $17.25M

Open	High	Low	Value	Volume
2.8¢	2.9¢	2.7¢	$10.03K	365.9K

Buyers (Bids)

No.	Vol.	Price($)
7	668702	2.7¢

Sellers (Offers)

Price($)	Vol.	No.
2.8¢	11840	2

View Market Depth

No.	Vol.	Price($)
7	668702	0.027
5	514425	0.026
5	315000	0.025
2	61707	0.024
1	393000	0.023

Price($)	Vol.	No.
0.028	11840	2
0.029	472024	8
0.030	1292320	15
0.031	466110	6
0.032	200000	1

Last trade - 16.10pm 24/06/2024 (20 minute delay)

AT1 (ASX) Chart

Definitely a good question to proffer the company. I agree it...

Shekel Brainweigh CEO Nir Leshem weighs in on AI adoption ahead of FY25

If you thought lithium was dead, think again. The Pilbara will be central to the next upswing

With financials holding the fort, materials must step up with some heavy lifting to stimulate stocks

Cultural heritage agreement puts Walford Creek exploration back on the map

Strike Energy secures $153 million for Perth Basin gas projects

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Definitely a good question to proffer the company. I agree it...

Top Stories

Shekel Brainweigh CEO Nir Leshem weighs in on AI adoption ahead of FY25

If you thought lithium was dead, think again. The Pilbara will be central to the next upswing

With financials holding the fort, materials must step up with some heavy lifting to stimulate stocks

Cultural heritage agreement puts Walford Creek exploration back on the map

Strike Energy secures $153 million for Perth Basin gas projects

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News